Bioheart and PharmaCell Open GMP Lab Facility in Europe
News Jun 05, 2006
This lab is an advanced research facility that also has GMP cell production capabilities to support research related to Bioheart's adult muscle stem cell technology.
Bioheart has developed MyoCell™, a cell therapy that involves extracting and culturing cells from a patient's own thigh muscle.
These cells are inserted back into the patient's damaged heart region via the MyoCath®, a minimally-invasive injection-catheter system.
"We are excited about the opening of this GMP facility that will support our research," said Howard J. Leonhardt, Chairman and CEO of Bioheart.
"We chose the Maastricht region due to its highly educated workforce and its ideal location with close proximity to top research institutes such as the University of Maastricht," he added.